Tatiana Scherz
Actelion
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Tatiana Scherz as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:48 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT02907177 · Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)Actelion · terminated · Multiple Sclerosis · study director
- Ph3NCT02425644 · Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple SclerosisActelion · completed · Multiple Sclerosis · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:48 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 09:48 UTC. The ranking covers the 200 most relevant of 5 PubMed records, and a shared surname and initials can bring in a namesake. All 5 on PubMed
- 730 citationsRCR 31.8
- Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.JAMA Neurol · 2021188 citationsRCR 13.4
- Out-of-hospital initiation of hypothermia in ST-segment elevation myocardial infarction: a randomised trial.Heart · 201936 citationsRCR 1.7
- Exploratory echocardiographic strain parameters for the estimation of myocardial infarct size in ST-elevation myocardial infarction.Clin Cardiol · 20216 citationsRCR 0.5
- An Exposure-Response Analysis of the Clinical Efficacy of Ponesimod in a Randomized Phase II Study in Patients with Multiple Sclerosis.Clin Pharmacokinet · 20215 citationsRCR 0.3